Skip to main content
SpringerLink
Log in

Cardioprotective Effect of Dexrazoxane in Patients with Breast Cancer Treated with Anthracyclines in Adjuvant Setting

A 10-Year Single Institution Experience

  • Original Research Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Background and objective

Anthracyclines are highly effective and widely used cytotoxic agents, but their application is often limited by cumulative dose-dependent cardiotoxicity. Dexrazoxane has been shown in several clinical trials to prevent the development of this serious toxicity. The aim of our study was to analyze the incidence of cardiac dysfunction over a 10-year period in patients with breast cancer who were treated with anthracycline-based regimens with addition of dexrazoxane, mainly in an adjuvant setting.

Methods

We conducted a retrospective analysis on a population of women with breast cancer treated at our institution between January 1993 and October 2003. We reviewed patients’ medical records and data on patient characteristics, treatment history, and adverse events that were collected, starting from the time of first visit before starting therapy, with the use of software created and designed for clinical records management in our institution (1999 OK-DH™). Patients underwent an ECG assessment prior to starting chemotherapy, and were clinically monitored for cardiac failure. Those who developed signs and symptoms suggestive of cardiac dysfunction underwent further ECG. If clinical findings indicated, echocardiography and further cardiologic investigations were performed. The main outcome measure was the development of signs and symptoms indicative of congestive heart failure (CHF).

Results

A total of 318 female patients were treated with an anthracycline (doxorubicin or epirubicin)-based combination chemotherapy regimen during this time, in most cases in the adjuvant setting (n = 285). Most patients (n = 302) had early-stage disease and only 16 women presented with metastatic disease with good life expectancy (at least 1 year). All patients received dexrazoxane 1000 mg/m2 intravenously prior to anthracycline administration during each chemotherapy cycle. The median follow-up duration was 35 months. During this time, five patients (1.57%) developed signs and symptoms of CHF. No patient at our institution died of heart failure during the period analyzed. Dexrazoxane was well tolerated, with no reports of adverse events associated with this drug.

Conclusions

The reported incidence of cardiotoxicity in this study represents a marked reduction compared with historical data for patients receiving anthracycline-based chemotherapy without dexrazoxane. Dexrazoxane appears to have a cardioprotective effect in women with early-stage or advanced breast cancer treated with anthracycline-based combination chemotherapy, mainly as an adjuvant treatment. Prospective, randomized, controlled clinical trials in adjuvant setting should be performed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Muggia FM, Green MD. New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol 1991; 11(1): 43–64.

    Article  PubMed  CAS  Google Scholar 

  2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869–79.

    Article  PubMed  CAS  Google Scholar 

  3. Michelotti A, Venturini M, Tibaldi C, et al. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat 2000; 59(2): 133–9.

    Article  PubMed  CAS  Google Scholar 

  4. Baldini E, Prochilo T, Salvadori B, et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br J Cancer 2004; 91(1): 45–9.

    Article  PubMed  CAS  Google Scholar 

  5. Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983; 52(1): 51–60.

    Article  PubMed  CAS  Google Scholar 

  6. Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65(5): 823–32.

    Article  PubMed  CAS  Google Scholar 

  7. Billingham ME, Bristow MR, Glatstein E, et al. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977; 1(1): 17–23.

    Article  PubMed  CAS  Google Scholar 

  8. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266(12): 1672–7.

    Article  PubMed  CAS  Google Scholar 

  9. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13(6): 819–29.

    Article  PubMed  CAS  Google Scholar 

  10. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91(5): 710–7.

    Google Scholar 

  11. Weiss AJ, Metter GE, Fletcher WS, et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976; 60(7): 813–22.

    PubMed  CAS  Google Scholar 

  12. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63(1): 37–45.

    Article  PubMed  CAS  Google Scholar 

  13. Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3(6): 818–26.

    PubMed  CAS  Google Scholar 

  14. Sells RA, Gilmore IT, Owen RR, et al. Reduction in doxorubicin toxicity following liposomal delivery. Cancer Treat Rev 1987; 14 (3–4): 383–7.

    Article  Google Scholar 

  15. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14(12): 3112–20.

    PubMed  CAS  Google Scholar 

  16. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16(11): 3502–8.

    PubMed  CAS  Google Scholar 

  17. Dardir M, Herman EH, Ferrans VJ. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 1989; 23(5): 269–75.

    Article  PubMed  CAS  Google Scholar 

  18. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197(4299): 165–7.

    Article  PubMed  CAS  Google Scholar 

  19. Zhang J, Herman EH, Ferrans VJ. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol 1993; 142(6): 1916–26.

    PubMed  CAS  Google Scholar 

  20. Herman EH, Ferrans VJ. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treat Rev 1990; 17 (2–3): 155–60.

    Article  Google Scholar 

  21. Doroshow JH. Anthracycline antibiotic-stimulated Superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 1983; 43(10): 4543–51.

    PubMed  CAS  Google Scholar 

  22. Doroshow JH, Locker GY, Baldinger J, et al. The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol 1979; 26(2): 285–95.

    PubMed  CAS  Google Scholar 

  23. Doroshow JH, Locker GY, Myers CE. Enzymatic defences of the mouse heart against reactive oxygen metabolites. J Clin Invest 1980; 65: 128–35.

    Article  PubMed  CAS  Google Scholar 

  24. Sobol MM, Amiet RG, Green MD. In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex. Mol Pharmacol 1992; 41(1): 8–17.

    PubMed  CAS  Google Scholar 

  25. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 1989; 26 (3–4): 378–85.

    Article  Google Scholar 

  26. Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 222(5191): 384–5.

    Article  PubMed  CAS  Google Scholar 

  27. Woodman RJ, Cysyk RL, Kline I, et al. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother Rep 1975; 59(4): 689–95.

    PubMed  CAS  Google Scholar 

  28. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130(1): 1–7.

    Article  PubMed  CAS  Google Scholar 

  29. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15(4): 1333–40.

    PubMed  CAS  Google Scholar 

  30. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14(2): 362–72.

    PubMed  CAS  Google Scholar 

  31. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16(1): 86–92.

    PubMed  CAS  Google Scholar 

  32. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15(4): 1318–32.

    PubMed  CAS  Google Scholar 

  33. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10(1): 117–27.

    PubMed  CAS  Google Scholar 

  34. ten Bokkel Huinink WW, Schreuder JE, Dubbleman R, et al. ICFF-187 protects against doxorubicin induced cardiomyopathy [abstract]. Ann Oncol 1992; 3 (Suppl. 3): 114.

    Google Scholar 

  35. Sparano JA, Speyer J, Gradishar WJ, et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 1999; 17(3): 880–6.

    PubMed  CAS  Google Scholar 

  36. Tetef ML, Synold TW, Chow W, et al. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res 2001; 7(6): 1569–76.

    PubMed  CAS  Google Scholar 

  37. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. In: 5th ed. Philadelphia (PA): Lippincott-Raven, 1997.

    Google Scholar 

  38. Erhart RH, Tutsch KD, Koeller JM, et al. Pharmacokinetics of ICRF-187 intravenous infusion in adult cancer patients. Cancer Res 1982; 42: 5255–61.

    Google Scholar 

  39. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 1998; 25(4 Suppl. 10): 66–71.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Editorial support for the preparation of this manuscript was provided by Wolters Kluwer Health Medical Communications. The authors have no conflicts of interest that are relevant to the content of this study.

Author information

Authors and Affiliations

  1. Oncology Unit, Ospedale Cardinal Massaia, Asti, Italy

    Franco Testore, Simona Milanese, Marco Ceste, Enrico de Conciliis, Giuseppe Parello, Claudio Lanfranco, Roberto Manfredi, Gianfranco Ferrero, Carlotta Simoni, Loredana Miglietta, Silvia Ferro, Lorena Giaretto & Giuseppina Bosso

  2. S.O.C. Oncologia, Ospedale Cardinal Massaia, Corso Dante 202, 14100, Asti, Italy

    Franco Testore

Authors
  1. Franco Testore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simona Milanese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Ceste
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enrico de Conciliis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Parello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claudio Lanfranco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Manfredi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gianfranco Ferrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carlotta Simoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Loredana Miglietta
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Silvia Ferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lorena Giaretto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Giuseppina Bosso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franco Testore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Testore, F., Milanese, S., Ceste, M. et al. Cardioprotective Effect of Dexrazoxane in Patients with Breast Cancer Treated with Anthracyclines in Adjuvant Setting. Am J Cardiovasc Drugs 8, 257–263 (2008). https://doi.org/10.2165/00129784-200808040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200808040-00005

Keywords

Search

Navigation